It has been shown that SOX9 is significantly overexpressed in high-grade pancreatic tumors and in chemotherapy-treated patients, compared to chemo-naive patients, and reduction in its expression is significant for the decrease in tumor growth and successes of combined chemotherapeutic regiments [49]. The gene discussed is SOX9; the disease is neoplasm.